Analyzing Ernexa Therapeutics (NASDAQ:ERNA) & OmniAb (NASDAQ:OABI)

Ernexa Therapeutics (NASDAQ:ERNA) and OmniAb (NASDAQ:OABI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, dividends, institutional ownership, profitability and valuation.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Ernexa Therapeutics and OmniAb, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ernexa Therapeutics	1	0	0	0	1.00
OmniAb	1	0	3	0	2.50

OmniAb has a consensus price target of $6.67, suggesting a potential upside of 260.36%. Given OmniAb’s stronger consensus rating and higher possible upside, analysts plainly believe OmniAb is more favorable than Ernexa Therapeutics.

Profitability

This table compares Ernexa Therapeutics and OmniAb’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Ernexa Therapeutics	N/A	-1,950.55%	-304.60%
OmniAb	-301.83%	-23.14%	-20.59%

Volatility & Risk

Ernexa Therapeutics has a beta of 6.25, indicating that its share price is 525% more volatile than the S&P 500. Comparatively, OmniAb has a beta of 0.13, indicating that its share price is 87% less volatile than the S&P 500.

Institutional and Insider Ownership

70.6% of Ernexa Therapeutics shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 4.5% of Ernexa Therapeutics shares are owned by company insiders. Comparatively, 8.6% of OmniAb shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Ernexa Therapeutics and OmniAb”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ernexa Therapeutics	$580,000.00	16.78	-$44.54 million	($3.01)	-0.41
OmniAb	$26.39 million	10.09	-$62.03 million	($0.58)	-3.19

Ernexa Therapeutics has higher earnings, but lower revenue than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than Ernexa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

OmniAb beats Ernexa Therapeutics on 9 of the 14 factors compared between the two stocks.

About Ernexa Therapeutics

Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

About OmniAb

OmniAb, Inc., a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts. Its OmniAb platform is the biological intelligence of proprietary transgenic animals, including OmniRat, OmniChicken, and OmniMouse that have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. The company's OmniFlic, a bispecific rat, and OmniClic, a bispecific chicken, designed for discovery of bispecific antibody applications; OmniTaur, which provides unique structural characteristics of cow antibodies for complex targets; and OmniDeep, a suite of in silico, an AI and machine learning tools for therapeutic discovery and optimization through various technologies and capabilities. OmniAb, Inc. was founded in 2012 and is headquartered in Emeryville, California.